Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...
FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...
There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the need for more robust data. Lack of data in certain populations rather than ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...
A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback